Nature Communications (Sep 2024)

10-hydroxy-2-decenoic acid prevents osteoarthritis by targeting aspartyl β hydroxylase and inhibiting chondrocyte senescence in male mice preclinically

  • Nana Geng,
  • Mengtian Fan,
  • Biao Kuang,
  • Fengmei Zhang,
  • Menglin Xian,
  • Lin Deng,
  • Cheng Chen,
  • Yiming Pan,
  • Jianqiang Chen,
  • Naibo Feng,
  • Li Liang,
  • Yuanlan Ye,
  • Kaiwen Liu,
  • Xiaoli Li,
  • Yu Du,
  • Fengjin Guo

DOI
https://doi.org/10.1038/s41467-024-51746-3
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 23

Abstract

Read online

Abstract Osteoarthritis is a degenerative joint disease with joint pain as the main symptom, caused by fibrosis and loss of articular cartilage. Due to the complexity and heterogeneity of osteoarthritis, there is a lack of effective individualized disease-modifying osteoarthritis drugs in clinical practice. Chondrocyte senescence is reported to participate in occurrence and progression of osteoarthritis. Here we show that small molecule 10-hydroxy-2-decenoic acid suppresses cartilage degeneration and relieves pain in the chondrocytes, cartilage explants from osteoarthritis patients, surgery-induced medial meniscus destabilization or naturally aged male mice. We further confirm that 10-hydroxy-2-decenoic acid exerts a protective effect by targeting the glycosylation site in the Asp_Arg_Hydrox domain of aspartyl β-hydroxylase. Mechanistically, 10-hydroxy-2-decenoic acid alleviate cellular senescence through the ERK/p53/p21 and GSK3β/p16 pathways in the chondrocytes. Our study uncovers that 10-hydroxy-2-decenoic acid modulate cartilage metabolism by targeting aspartyl β-hydroxylase to inhibit chondrocyte senescence in osteoarthritis. 10-hydroxy-2-decenoic acid may be a promising therapeutic drug against osteoarthritis.